Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer launches Dupuytren’s contracture drug Xiapex in UK

Pfizer launches Dupuytren’s contracture drug Xiapex in UK

7th April 2011

Pfizer has announced the UK availability of Xiapex, its innovative new treatment option for Dupuytren's contracture.

The drug has been ratified as the first injectable treatment for the condition to be launched in Britain after it demonstrated its efficacy in pivotal clinical trials.

Dupuytren's contracture is a consequence of the progressive ailment known as Dupuytren's disease, which causes an excess build-up of collagen under the skin in hands and causes fingers to become permanently contracted towards the palm.

It is hoped that this new drug can offer a viable alternative to surgery when treating a condition that can be significantly detrimental to patients' quality of life.

Jonathan Jones, medical director of the speciality care business unit at Pfizer, said: "The development of a new treatment like Xiapex is an important step forward for patients with Dupuytren's contracture."

Earlier this week, Pfizer announced the sale of its drug delivery business unit Capsugel to Kohlberg Kravis Roberts, an international investment company.ADNFCR-8000103-ID-800490876-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.